DOYLESTOWN, PA — Aprea Therapeutics Inc. (Nasdaq: APRE) is building patent protection around its two precision-oncology programs that could extend into the 2040s, reinforcing the intellectual-property position behind drug candidates ...
ADVERTISEMENT
ADVERTISEMENT
2026 Copyright © News-Matic.com. All Rights Reserved
